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OBJECTIVE: The purpose of this descriptive study was to
examine the most common treatment classes based on drug class
and the describe the differences in prescribing methods across age
groups. METHODS: Information was collected from the Phar-
Metrics Integrated Patient-centric Database, a large collection of
administrative claims. At the time of this analysis in 2004, there
weremore than 80 public and private health care plans included in
the database, representing approximately 9.6 million unique
patients. Analysis was performed using the Total Resource
Utilization (TRU) Benchmarks process, a descriptive methodol-
ogy organizes and separates information, from a third-party
database, into accessible benchmarks for comparison. These
resultswere then factored against age groups. The age group break
down is as follows: 12–14, 15–17, 18–24, and 24–35. RESULTS:
The most commonly prescribed medications in the United States
for acne were: New generation retinoid products, benzoyl
peroxide-based combo products , topical corticosteroids by Rx
only, Topical antibiotics, common topical retinoid products, oral
anti-biotics, as well as antidepressants and benzodiazepines in
some age categories. The age breakdown was as follows: Ages
12–14: Oral antibiotics (38.8%), Benzoyl peroxide-based prod-
ucts (32.7%), New generation retinoid products (30.1%), Topical
antibiotics (21.7%), Common topical retinoid products (20.7%)
Ages 15–17: Oral antibiotics (55.0%) Benzoyl peroxide-based
products (32.0%) New generation retinoid products (31.3%)
Topical antibiotics (21.3%), Common topical retinoid products
(21.1%) Ages 18–24: Oral antibiotics (52.6%), New generation
retinoid products (28.3%), Benzoyl peroxide-based products
(26.8%), Oral contraceptives (24.8%), Topical antibiotics
(20.4%) Ages 25–35: Oral antibiotics (44.2%), Oral contracep-
tives (33.0%), Topical antibiotics (22.1%), Benzoyl peroxide-
based products (21.5%), New generation retinoid products
(20.1%). CONCLUSION: It was determined that signiﬁcant dif-
ferences by medication type do in fact occur in all the different age
groups. The discrepancies can be clearly observed and on physi-
cian to physician bases, one can determine if their own particular
prescribing method is appropriate.
URINARY/KIDNEY DISORDERS—
Clinical Outcomes Studies
PUK1
CHRONIC KIDNEY DISEASE (CKD) AMONG INPATIENTS
WITH REDUCED KIDNEY FUNCTION (RKF) ON
HOSPITAL ADMISSION
Yu HT1, Barlev A2, Emons MF1, Fiske KS3, Curkendall S4
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Amgen,Thousand Oaks,
CA, USA, 3Cerner Corporation, Kansas City, MO, USA, 4Cerner
LifeSciences,Vienna,WV, USA
OBJECTIVE: To evaluate the prevalence of chronic kidney
disease (CKD) in hospitalized patients and determine the propor-
tion of these patients with/without a diagnosis of CKD based on
estimated glomerular ﬁltration rates (eGFR). METHODS: A ret-
rospective analysis of US hospital data in the Cerner Health
Facts® database during January 2000 and March 2007 was
conducted. Inclusion criteria were age 18 years, a SCr measure-
ment 3–18 months before hospital admission and seven days
before or three days after hospital admission. Patients who had
dialysis, acute renal failure and/or mixed inpatient eGFR (some
values <60 and others =60 mL/min/1.73m2) were excluded. To
minimize bias and misclassiﬁcation due to hospitalization cir-
cumstances, 2 eGFR values <60 mL/min/1.73m2 were used to
designate patients with CKD. The ﬁrst eGFR was determined
from the closest SCr measurement within 3–18 months before
hospitalization and the second eGFR was determined using a
SCr seven days before or three days of hospital admission. The
MDRD-4 equation was used to calculate eGFR. RESULTS: Of
the 1,265,014 patients hospitalized over the seven years evalua-
tion, 193,221 met the inclusion criteria. Approximately 21% of
patients were subsequently excluded for dialysis, acute renal
failure, and/or mixed eGFR (n = 40,937). Overall, 27% of
patients (n = 41,495) had an eGFR < 60 mL/min/1.73m2 at
admission. Of these, 81% (n = 33,443) had an eGFR < 60 mL/
min/1.73m2 prior to admission. Of this subset likely to have CKD
based on chronically low eGFR, only 26% (n = 8,560) had a
diagnosis of CKD at admission based on ICD-9-CM diagnosis.
CONCLUSION: Our ﬁndings suggest that most patients with
RKF upon hospital admission may have CKD. Of these, few
seem to have supportive CKD diagnosis codes. Identiﬁcation and
diagnosis of this patient population during hospitalization may
provide a unique opportunity to improve disease management
during the inpatient stay or after discharge, and may result in
earlier nephrology referrals if appropriate.
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OBJECTIVE: To determine the association of blood pressure
(BP) control and trajectory of renal function over seven years in
a cohort of hypertensive veterans; and to determine the associa-
tion between different classes of antihypertensive medications
and renal function quantiﬁed by glomerular ﬁltration rate (GFR).
METHODS: Data were obtained from Southern Arizona Veter-
ans’ Affairs Health Care System from January 1, 2000 through
December 31, 2006. Inclusion criteria consisted of veterans 21
and < 90 years of age with at least two systolic BP measurements,
and two serum creatinine measurements at least 90 days apart
who had an ICD-9 hypertension diagnosis. Veterans were
divided into time-varying controlled or uncontrolled hyperten-
sion groups based upon JNC-7 deﬁnitions. Factors examined
included age, sex, race/ethnicity membership, and antihyperten-
sive medication use. Medication categories included angiotensin
converting enzyme inhibitor (ACE), beta-blocker (BB), or
calcium channel blocker (CCB) monotherapy, or combinations of
ACE, BB, and CCB. GFR was estimated using serum creatinine
level, age, sex, and race/ethnicity. Analysis was performed using
a generalized linear mixed model with patient as random effect.
RESULTS: A total of 25,819 subjects met inclusion/exclusion
criteria: 12,411 with controlled and 13,406 with uncontrolled
BP. Males comprised 11,669 of controlled and 12,864 of uncon-
trolled groups. Mean age (SD) at index was 64.9(11.9) and
66.6(11.6) years in the controlled and uncontrolled groups
respectively. Annual decline in GFR was 0.32 ml/–/1.73m2 after
adjusting for covariates and medication use. There was a signiﬁ-
cant interaction between BP control and age (p < 0.001). ACE,
BB, CCB use was associated with higher GFR (1.1, 95% CI
0.7–1.4; 0.5, 95% CI 0.1–0.8; and 0.8, 95% CI 0.2–1.3 ml/
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